angle-down cancel chevron-down close-x close-x-menu envelope home3 th-menu resource-icons-01 resource-icons-02 resource-icons-03 resource-icons-04 resource-icons-05-(1) resource-icons-06-(1) resource-icons-07 resource-8 walleticon_2-ab_shrunk search search-plus share three-bars twitter PLAY BUTTON Copy 2 Created with Sketch. patient-site

Access & Reimbursement

Getting Patients Started on IDHIFA®

IDHIFA® is only available through the list of contracted specialty pharmacies or through authorized distributors for in-office dispensing by community physicians, hospitals, institutions, Veterans Affairs, and Department of Defense.

Specialty Pharmacies and Authorized Distributors

Reimbursement information

National Drug Codes (NDCs)
10-digit NDC 11-digit NDCa Dosage strength Description
59572-705-30 59572-0705-30 50 mg/tablet Bottle of 30 pale yellow-to-yellow oval-shaped tablets; each film-coated tablet is debossed “ENA” on one side and “50” on the other side.
59572-710-30 59572-0710-30 100 mg/tablet Bottle of 30 pale yellow-to-yellow capsule-shaped tablets; each tablet is debossed “ENA” on one side and “100” on the other side.
National Drug Codes (NDCs)
10-digit NDC 59572-705-30 59572-710-30
11-digit NDCa 59572-0705-30 59572-0710-30
Dosage strength 50 mg/tablet 100 mg/tablet
Description Bottle of 30 pale yellow-to-yellow oval-shaped tablets; each film-coated tablet is debossed “ENA” on one side and “50” on the other side. Bottle of 30 pale yellow-to-yellow capsule-shaped tablets; each tablet is debossed “ENA” on one side and “100” on the other side.

aThe red zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.


IDHIFA® (enasidenib) Bottles and Product Information

How supplied

  • The 50-mg and 100-mg doses are supplied in bottles with a desiccant canister


  • Store tablets at 20°C-25°C (68°F-77°F); excursions permitted between 15°C-30°C (59°F-86°F)
  • Keep the bottle tightly closed
  • Store in the original bottle (with a desiccant canister) to protect from moisture

Commonly used ICD-10 Codes*

  • C92: Myeloid leukemia
    • C92.0: Acute myeloblastic leukemia
      • C92.00: Acute myeloblastic leukemia, not having achieved remission
      • C92.01: Acute myeloblastic leukemia, in remission
      • C92.02: Acute myeloblastic leukemia, in relapse

*When selecting diagnosis codes, providers should consult a current ICD-10-CM manual and always select the most appropriate diagnosis code(s) with the highest level of detail to describe a patient’s actual condition.

Bristol Myers Squibb Access Support®

BMS Access Support® Can Provide 
Patient Access and Reimbursement Assistance
Bristol Myers Squibb is committed to helping patients gain access to their prescribed BMS medications. 
That’s why we offer BMS Access Support. BMS Access Support provides resources to help patients understand 
their insurance coverage. In addition, we can share information on sources of financial support, including 
co-pay assistance for eligible commercially insured patients.
BMS Access Support Icon
How BMS Access Support May HelpFind out how BMS can work with patients and their healthcare 
providers to help access a prescribed BMS medication.
BMS Financial Support Icon
Financial Support OptionsThere may be programs and services that could help with the 
cost of treatment. Learn about what options are available.
Additional Resources Icon
Additional ResourcesWe provide videos, tools, and other resources that may help 
with your access and reimbursement needs.
Have Questions About Our Program 
or Possible Financial Support?
If you have questions about coverage for a prescribed BMS medication, BMS Access Support may be able to 
help. Patients and their healthcare provider can complete an enrollment form to learn about programs that 
may be of assistance. Visit our website or contact BMS Access Support to learn more.
Cellphone Icon
Call Bristol Myers Squibb Access Support at 
1-800-861-0048, 8 am to 8 pm ET, Monday-Friday
The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider 
and the patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.


IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

Toggle Toggle

Important Safety Information


Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.



Differentiation Syndrome: See Boxed WARNING. In the clinical trial, 14% of patients treated with IDHIFA experienced differentiation syndrome, which may be life-threatening or fatal if not treated. Differentiation syndrome has been observed with and without concomitant hyperleukocytosis, in as early as 1 day and up to 5 months after IDHIFA initiation. Symptoms in patients treated with IDHIFA included acute respiratory distress represented by dyspnea and/or hypoxia and need for supplemental oxygen; pulmonary infiltrates and pleural effusion; renal impairment; fever; lymphadenopathy; bone pain; peripheral edema with rapid weight gain; and pericardial effusion. Hepatic, renal, and multi-organ dysfunction have also been observed. If differentiation syndrome is suspected, initiate systemic corticosteroids and hemodynamic monitoring until improvement. Taper corticosteroids only after resolution of symptoms. Differentiation syndrome symptoms may recur with premature discontinuation of corticosteroids. If severe pulmonary symptoms requiring intubation or ventilator support and/or renal dysfunction persist for more than 48 hours after initiation of corticosteroids, interrupt IDHIFA until signs and symptoms are no longer severe. Hospitalization for close observation and monitoring of patients with pulmonary and/or renal manifestation is recommended.

Embryo-Fetal Toxicity: Based on animal embryo-fetal toxicity studies, IDHIFA can cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with IDHIFA and for at least 2 months after the last dose. Advise pregnant women of the potential risk to the fetus.


  • The most common adverse reactions (≥20%) included total bilirubin increased (81%), calcium decreased (74%), nausea (50%), diarrhea (43%), potassium decreased (41%), vomiting (34%), decreased appetite (34%), and phosphorus decreased (27%)
  • The most frequently reported ≥Grade 3 adverse reactions (≥5%) included total bilirubin increased (15%), potassium decreased (15%), phosphorus decreased (8%), calcium decreased (8%), diarrhea (8%), differentiation syndrome (7%), non-infectious leukocytosis (6%), tumor lysis syndrome (6%), and nausea (5%)
  • Serious adverse reactions were reported in 77.1% of patients. The most frequent serious adverse reactions (≥2%) were leukocytosis (10%), diarrhea (6%), nausea (5%), vomiting (3%), decreased appetite (3%), tumor lysis syndrome (5%), and differentiation syndrome (8%). Differentiation syndrome events characterized as serious included pyrexia, renal failure acute, hypoxia, respiratory failure, and multi-organ failure


Coadministration of IDHIFA increases the exposure of OATP1B1, OATP1B3, BCRP, and P‑glycoprotein (P‑gp) substrates, which may increase the incidence and severity of adverse reactions of these substrates. If coadministered, decrease the dosage of the substrate as recommended in the respective prescribing information and as clinically indicated.


Because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with IDHIFA and for at least 2 months after the last dose.

Please see full Prescribing Information, including Boxed WARNING.

IDHIFA® (enasidenib) logo

Complete the form below to share this page.

  • Bristol Myers Squibb does not collect this personal information. Privacy Policy
IDHIFA® (enasidenib) logo

You are about to leave the IDHIFA® healthcare professional website and are going to a website that is not operated by Bristol Myers Squibb. Bristol Myers Squibb is not responsible for the content or availability of linked sites. Also, please be aware that the security and privacy policies on these sites may be different than Bristol Myers Squibb policies, so please read third-party privacy and security policies closely.

Do you wish to leave this site?

Celgene Commercial Co-pay Program Terms and Conditions


Patients must meet the following criteria to enroll:

  • Covered by commercial or private insurance
  • Reside in the United States or US territory
  • Not participating in a federal or state-funded healthcare program, including, but not limited to, Medicare (Parts B, C, and D) or Medicaid, Medigap, CHAMPUS, VA, DOD, or Tricare
  • Gross annual household income must not exceed $100,000
    • Gross household income is the total income before income tax deductions from all people living in your household. Gross income refers not only to the salaries and benefits received, but also to receipts from any personal business, investments, dividends, and other income

Program Benefits

  • For Celgene oral hematology products, Celgene provides assistance to reduce the co-pay of eligible patients to $25 per prescription with a maximum benefit of $10,000 per enrollment period
  • For Celgene IV products, the Program will cover the co-pay for each prescription of a Celgene product up to a maximum of $10,000 per enrollment period
    • In order to receive the Program benefits for a Celgene IV product, patients or their providers must submit an Explanation of Benefits (EOB) form
  • Patients are responsible for any costs that exceed the Program’s $10,000 maximum
  • The Program will not cover, and shall not be applied toward, the cost of any dosing procedure, any other healthcare provider service or supply charges or other treatment costs, or any costs associated with a hospital stay

Program Timing

  • If eligible, patients will be enrolled from the date of enrollment through the end of the then current calendar year

Additional Terms and Conditions of the Celgene Commercial Co-pay Programs

  • Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Program
  • Acceptance of this offer confirms that this offer is consistent with your insurance and that you will report the value of the co-pay assistance you receive as may be required by your insurance provider
  • Only valid in the United States and US territories; this offer is void where prohibited by law, taxed or restricted. Absent a change in Massachusetts law, effective July 1, 2019, Massachusetts residents will no longer be eligible to participate in this Program
  • The Program benefits are nontransferable
  • Acceptance in this Program is not conditioned on any past, present, or future purchase, including additional doses
  • The Program cannot be combined with any other coupon, rebate, voucher, free trial, or similar offer
  • The Program is not insurance
  • Celgene reserves the right to rescind, revoke, or amend this Program at any time without notice
IDHIFA® (enasidenib) logo

You are now leaving the healthcare professional website.


Do you wish to leave this site?

IDHIFA® (enasidenib) logo

You are now leaving


Click "OK" to proceed or "Cancel" to return to

IDHIFA® (enasidenib) logo

Please select who you are:

This site is intended for U.S. audiences only.